FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366991115> ?p ?o ?g. }

• W4366991115 endingPage "1267" @default.
• W4366991115 startingPage "1267" @default.
• W4366991115 abstract "Trifluridine/tipiracil (FTD/TPI) is an oral antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue that inhibits cell proliferation following its incorporation into DNA, and tipiracil that helps maintain the blood concentration of trifluridine by inhibiting the enzyme thymidine phosphorylase which inactivates trifluridine. It is approved as a third-line treatment option for patients with metastatic colorectal cancer (mCRC) and is administered at 35 mg/m2 two times daily from day 1 to 5 and from day 8 to 12 every 28 days. The aim of this investigator-initiated retrospective study (RETRO-TAS; NCT04965870) was to document real-world data on the clinical efficacy of FTD/TPI in patients with chemorefractory mCRC.The clinical characteristics of patients with mCRC treated with FTD/TPI in 8 Cancer Centres were collected to assess physician's choice in the third or beyond line of treatment as well as the duration of treatment, dose modification, and toxicity. In addition, other important prognostic features related to mCRC such as molecular profile, performance status (PS), and primary site were analyzed. Statistical analysis for progression-free survival (PFS), overall survival (OS), 6-/8-month PFS rate and disease control rate (DCR) along with Cox regression model, Kaplan-Meier curves, and log-rank tests were carried out by using Stata/MP 16.0 for Windows.From October 2018 to October 2021, a total of 200 patients with mCRC and a median age of 67.0 (IQR 58.0, 75.0) years were treated with FTD/TPI. Τhe median follow-up time was 14 months (IQR 7, 23), 158 PDs and 106 deaths were reported at the time of this analysis. Of all the patients, 58% were males and 58% had mCRC at diagnosis. The molecular analysis identified mutations in KRAS (52%), NRAS (5%), HER2 (3.5%), BRAF (3.5%), and MSI (9%). Previous treatments included radical surgery in 51.5% and adjuvant chemotherapy in 39.5% of patients. FTD/TPI was administered in the third- (70.5%), fourth- (17.0%), or fifth-line (12.5%) treatment setting. Serious adverse events related to FTD/TPI included neutropenia (2%), anaemia (1%), thrombocytopenia (0.5%), diarrhoea (0.5%), nausea (0.5%), and fatigue (4%). A reduction of FTD/TPI dose, delay of next cycle initiation, and shorter duration were reported in 25%, 31%, and 14.5% of patients, respectively. Of all the patients 71.5% received FTD/TPI as monotherapy, 24.5% in combination with bevacizumab, and 4.0% with an anti-EGFR agent. The median FTD/TPI treatment duration was 119.5 days and 81% of patients discontinued treatment due to progressive disease. The DCR recorded by investigators' assessment was 45.5%. The median PFS was 4.8 and the median OS was 11.4 months. The 6- and the 8-month PFS rate was 41.4% and 31.5%, respectively. In the multivariate analysis, PS > 1 and presence of liver and lung metastasis were adversely associated with PFS and OS whereas mutational status and tumor sidedness were not.RETRO-TAS is a real-world observational study that confirms and adds on the findings of the pivotal RECOURSE Phase III study in relation to the efficacy of FTD/TPI in the third-line setting and in all subgroups of patients regardless of mutational status and sidedness." @default.
• W4366991115 created "2023-04-27" @default.
• W4366991115 creator A5005263264 @default.
• W4366991115 creator A5005489735 @default.
• W4366991115 creator A5011764519 @default.
• W4366991115 creator A5022153585 @default.
• W4366991115 creator A5027188702 @default.
• W4366991115 creator A5027312076 @default.
• W4366991115 creator A5029532846 @default.
• W4366991115 creator A5032683578 @default.
• W4366991115 creator A5041696013 @default.
• W4366991115 creator A5043938652 @default.
• W4366991115 creator A5047656028 @default.
• W4366991115 creator A5054990997 @default.
• W4366991115 creator A5059034975 @default.
• W4366991115 creator A5084550691 @default.
• W4366991115 creator A5085021572 @default.
• W4366991115 creator A5086594420 @default.
• W4366991115 creator A5090185547 @default.
• W4366991115 date "2023-04-24" @default.
• W4366991115 modified "2023-10-14" @default.
• W4366991115 title "RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer" @default.
• W4366991115 cites W2088438184 @default.
• W4366991115 cites W2141434947 @default.
• W4366991115 cites W2151180605 @default.
• W4366991115 cites W2162627860 @default.
• W4366991115 cites W2397449980 @default.
• W4366991115 cites W242040007 @default.
• W4366991115 cites W2588031139 @default.
• W4366991115 cites W2740758819 @default.
• W4366991115 cites W2774682757 @default.
• W4366991115 cites W2794202130 @default.
• W4366991115 cites W2937226633 @default.
• W4366991115 cites W2966636329 @default.
• W4366991115 cites W3003103377 @default.
• W4366991115 cites W3029346583 @default.
• W4366991115 cites W3030149115 @default.
• W4366991115 cites W3045266223 @default.
• W4366991115 cites W3079866290 @default.
• W4366991115 cites W3130224122 @default.
• W4366991115 cites W3167942036 @default.
• W4366991115 cites W3177570662 @default.
• W4366991115 cites W3198655926 @default.
• W4366991115 cites W3214899089 @default.
• W4366991115 cites W3217002942 @default.
• W4366991115 cites W4293149746 @default.
• W4366991115 cites W4307401860 @default.
• W4366991115 cites W4317862819 @default.
• W4366991115 doi "https://doi.org/10.3390/biomedicines11051267" @default.
• W4366991115 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37238938" @default.
• W4366991115 hasPublicationYear "2023" @default.
• W4366991115 type Work @default.
• W4366991115 citedByCount "0" @default.
• W4366991115 crossrefType "journal-article" @default.
• W4366991115 hasAuthorship W4366991115A5005263264 @default.
• W4366991115 hasAuthorship W4366991115A5005489735 @default.
• W4366991115 hasAuthorship W4366991115A5011764519 @default.
• W4366991115 hasAuthorship W4366991115A5022153585 @default.
• W4366991115 hasAuthorship W4366991115A5027188702 @default.
• W4366991115 hasAuthorship W4366991115A5027312076 @default.
• W4366991115 hasAuthorship W4366991115A5029532846 @default.
• W4366991115 hasAuthorship W4366991115A5032683578 @default.
• W4366991115 hasAuthorship W4366991115A5041696013 @default.
• W4366991115 hasAuthorship W4366991115A5043938652 @default.
• W4366991115 hasAuthorship W4366991115A5047656028 @default.
• W4366991115 hasAuthorship W4366991115A5054990997 @default.
• W4366991115 hasAuthorship W4366991115A5059034975 @default.
• W4366991115 hasAuthorship W4366991115A5084550691 @default.
• W4366991115 hasAuthorship W4366991115A5085021572 @default.
• W4366991115 hasAuthorship W4366991115A5086594420 @default.
• W4366991115 hasAuthorship W4366991115A5090185547 @default.
• W4366991115 hasBestOaLocation W43669911151 @default.
• W4366991115 hasConcept C121608353 @default.
• W4366991115 hasConcept C123321153 @default.
• W4366991115 hasConcept C126322002 @default.
• W4366991115 hasConcept C143998085 @default.
• W4366991115 hasConcept C167135981 @default.
• W4366991115 hasConcept C2776735402 @default.
• W4366991115 hasConcept C2780456651 @default.
• W4366991115 hasConcept C50382708 @default.
• W4366991115 hasConcept C526805850 @default.
• W4366991115 hasConcept C71924100 @default.
• W4366991115 hasConcept C90924648 @default.
• W4366991115 hasConceptScore W4366991115C121608353 @default.
• W4366991115 hasConceptScore W4366991115C123321153 @default.
• W4366991115 hasConceptScore W4366991115C126322002 @default.
• W4366991115 hasConceptScore W4366991115C143998085 @default.
• W4366991115 hasConceptScore W4366991115C167135981 @default.
• W4366991115 hasConceptScore W4366991115C2776735402 @default.
• W4366991115 hasConceptScore W4366991115C2780456651 @default.
• W4366991115 hasConceptScore W4366991115C50382708 @default.
• W4366991115 hasConceptScore W4366991115C526805850 @default.
• W4366991115 hasConceptScore W4366991115C71924100 @default.
• W4366991115 hasConceptScore W4366991115C90924648 @default.
• W4366991115 hasIssue "5" @default.
• W4366991115 hasLocation W43669911151 @default.
• W4366991115 hasLocation W43669911152 @default.
• W4366991115 hasLocation W43669911153 @default.

• next